ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Vigonvita Life Sciences clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 39 studies whose lead sponsor is Vigonvita Life Sciences. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Vigonvita Life Sciences with Eli Lilly and Bristol-Myers Squibb →

Pipeline: 8 programs

Each counted once: 8 with a study Vigonvita Life Sciences leads registered in the last two years.

  • Phase 1
  • Phase 2

5 from the earlier phases, besides the phase-3 view.

Program
VV119Phase 2 · 4 live · Schizophrenia · primary completion Oct 2027☆ Track
VV913Phase 2 · 4 live · Premature Ejaculation · primary completion Dec 2026☆ Track
LV232Phase 2 · 1 live · Depressive Disorder, Major · primary completion Sep 2027☆ Track
Simenafil Hydrochloride Tablets 2.5 mgPhase 2 · 1 live · Alzheimer Disease · primary completion Sep 2028☆ Track
VV261Phase 1 · 2 live · primary completion Nov 2026☆ Track

3 more — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Vigonvita Life Sciences’ own registered studies; Vigonvita Life Sciences’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Vigonvita Life Sciences’ studies test, most open studies first — 6 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

7 of Vigonvita Life Sciences’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 3D
  3. J’27
  4. F
  5. M
  6. A
  7. 1M
  8. J
  9. J
  10. A
  11. 1S
  12. 1O
  13. N

Add all 7 to your calendar (.ics) → With an account.

All 39 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1231%Recruiting 7 · Not yet recruiting 5
  • Under way, not recruiting13%
  • Completed2667%

Phase

  • Phase 127
  • Phase 28
  • Phase 33
  • Early Phase 11

Where

Over the years

  1. 19
  2. 20
  3. 21
  4. 22
  5. 23
  6. 24
  7. 25
  8. 1026

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Vigonvita Life Sciences.

  • Vigonvita Life Sciences
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    39 studies

Focus areas

Conditions Vigonvita Life Sciences leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 39 of 39.